Discharge Outcomes of Severely Sick Patients Hospitalized with Multidrug-Resistant Tuberculosis, Comorbidities, and Serious Adverse Events in Kyrgyz Republic, 2020–2022

Author:

Alumkulova Gulzat1,Hazoyan Anna23,Zhdanova Elena1,Kuznetsova Yuliia4ORCID,Tripathy Jaya Prasad5,Sargsyan Aelita2ORCID,Goncharova Olga1,Kadyrov Meder1,Istamov Kylychbek6,Ortuño-Gutiérrez Nimer7ORCID

Affiliation:

1. National Center for Tuberculosis, Bishkek 720020, Kyrgyzstan

2. Tuberculosis Research and Prevention Centre (TBRPC), Yerevan 0014, Armenia

3. Internal Medicine (Gastroenterology and Hepatology) Department, Yerevan State Medical University, Yerevan 0025, Armenia

4. Alliance for Public Health, 01601 Kyiv, Ukraine

5. All India Institute of Medical Sciences, Nagpur 441108, India

6. School of Medicine, Osh State University, Osh City 723500, Kyrgyzstan

7. Damien Foundation, 1081 Brussels, Belgium

Abstract

Patients with multidrug-resistant tuberculosis (MDR-TB) who have comorbidities, complications, and experience serious adverse events (SAEs) are at substantial risk of having unfavorable hospital outcomes. We assessed characteristics and discharge outcomes of 138 MDR-TB patients hospitalized in the National Referral Center of Bishkek, Kyrgyz Republic, from January 2020 to August 2022. The main clinical characteristics included pulmonary complications (23%), malnutrition (33%), severe anemia (17%), diabetes mellitus (13%), viral hepatitis B and C (5%), and HIV infection (3%). Of those patients, 95% were successfully managed and discharged from hospital. Seven patients had unfavorable discharge outcomes (three patients died and four had a worsened clinical condition). Comorbidities (diabetes, and/or HIV), severe anemia, pulmonary complications, cardiovascular disorders, alcohol abuse, and SAEs were associated with unfavorable discharge outcomes. Sixty-five percent of the patients had SAEs, with electrolyte imbalance (25%), gastrointestinal disease (18%), hepatotoxicity (16%), and anemia (14%) being the most frequent. Successful resolution occurred in 91% of patients with SAEs. In summary, our study documented that sick patients who were hospitalized with MDR-TB were well managed and had good hospital discharge outcomes, despite the fact that they had comorbidities, complications, and SAEs. This information should assist in the referral and management of such patients in the future.

Funder

USAID

Publisher

MDPI AG

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology

Reference22 articles.

1. World Health Organization (2022, May 05). WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment—Drug-Susceptible Tuberculosis Treatment. 24 May 2022 Guideline. Available online: https://www.who.int/publications/i/item/9789240048126.

2. World Health Organization (2022, November 30). Global Tuberculosis Report 2022. Available online: https://www.who.int/publications/i/item/9789240061729.

3. World Health Organization (2022, May 05). Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB). Available online: https://apps.who.int/iris/rest/bitstreams/1420701/retrieve.

4. World Health Organization (2022, May 05). Global Tuberculosis Report 2016. Available online: https://www.who.int/publications/i/item/9789241565394.

5. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis;Maug;Am. J. Respir. Crit. Care Med.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3